The most common treatment-related adverse events were indirect hyperbilirubinemia (38%) and nausea (23%), and IDH-inhibitor-associated differentiation syndrome (IDH-DS) was one of the most frequent high-grade adverse events (6%) (12). This evidence concerns the gene IDH1 and Dravet syndrome.